ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems

In 'real-life', the Nordic score guides Erythropoietic stimulating agent (ESA) use in lower-risk myelodysplastic syndrome (MDS) with predicted response rates of 25% or 74%. As new treatments emerge, a more discriminating score is needed. To validate existing ESA predictive scores and devel...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2017-10, Vol.92 (10), p.1037-1046
Main Authors: Buckstein, Rena, Balleari, Enrico, Wells, Richard, Santini, Valeria, Sanna, Alessandro, Salvetti, Chiara, Crisà, Elena, Allione, Bernardino, Danise, Paolo, Finelli, Carlo, Clavio, Marino, Poloni, Antonella, Salvi, Flavia, Cilloni, Daniela, Oliva, Esther Natalie, Musto, Pellegrino, Houston, Brett, Zhu, Nancy, Geddes, Michelle, Leitch, Heather, Leber, Brian, Sabloff, Mitchell, Nevill, Thomas J, Yee, Karen W, Storring, John M, Francis, Janika, Maurillo, Luca, Latagliata, Roberto, Spiriti, Maria Antonietta Aloe, Andriani, Alessandro, Piccioni, Anna Lina, Fianchi, Luana, Fenu, Susanna, Gumenyuk, Svitlana, Buccisano, Francesco
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Canada - epidemiology
Databases, Factual
Erythropoietin
Female
Hematinics - therapeutic use
Hematology
Humans
International Cooperation
Italy - epidemiology
Logistic Models
Male
Multivariate analysis
Myelodysplastic syndrome
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - mortality
Predictive Value of Tests
Prognosis
Prospective Studies
Registries
Response rates
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 'real-life', the Nordic score guides Erythropoietic stimulating agent (ESA) use in lower-risk myelodysplastic syndrome (MDS) with predicted response rates of 25% or 74%. As new treatments emerge, a more discriminating score is needed. To validate existing ESA predictive scores and develop a new score that identifies non-responders. ESA-treated patients were identified in 3 MDS registries in Italy and Canada (FISM 555, GROM 233, and MDS-CAN 208). Clinical and disease-related variables were captured. Nordic, MDS-CAN, and IPSS-R-based ESA scores were calculated and documented ESA responses compared. 996 ESA-treated patients were identified. Overall response rate (ORR) was 59%. The database was randomly divided into balanced derivation (n = 463) and validation (n = 462) cohorts. By multivariate analysis, transfusion independence, erythropoietin (EPO) level
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.24842